Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2018

View Archived Issues

Positive outcome from European decentralized procedure for Ferring's Testavan

Elthera generates preclinical proof-of-concept data with anti-L1CAM antibodies

EMA accepts type II variation application for Xtandi in non-metastatic CRPC

TissueGene changes name to Kolon TissueGene

Japan Tobacco and Rohto sign exclusive Japanese license agreement for JTE-052

eTheRNA completes low-dose cohort enrollment in phase Ib study of ECI-006 for melanoma

BMS-986166: a partial agonist of S1P1 with reduced pulmonary and cardiovascular toxicity

Bavarian Nordic partners with U.S. DoD to develop equine encephalitis virus vaccine

[225Ac]-PSMA radioligand therapy safe and effective in mCRPC patients

Valneva releases phase I interim data on Lyme vaccine candidate VLA-15

MicroRNA 520a is a potential prognostic biomarker of hepatocellular carcinoma

Novel HBV-replication inhibitors discovered at Gilead

Rutherrin shown to destroy human brain cancer stem cells

Lycera patents new Rho-associated protein kinase 1/2 inhibitors

Novel IDO-1 inhibitors presented by Bristol-Myers Squibb

Institute of Radiation Medicine presents novel compounds protecting against radiation

Sunshine Lake Pharma describes new influenza A virus H1N1 inhibitors

Mereo announces topline phase IIb results for BGS-649 to treat hypogonadotropic hypogonadism

Advaxis initiates phase I study of ADXS-NEO in solid tumors

Crinetics Pharmaceuticals' CRN-00808 shows promise in phase I acromegaly trial

Phase I data reported for intravesical VPM-1002BC in non-muscle invasive bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...